Sinovac Biotech Ltd
NASDAQ: SVA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-29
Sinovac Biotech Ltd (SVA) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for SVA.
Valued
Fundamentals support the current valuation. Strong combination of growth, quality, and price.
SVA historical valuation range
Where current P/E sits in SVA's own 5Y range.
SVA intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
SVA valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 6.66x
P/S Ratio — History
Current: 1.83x
Is SVA overvalued in 2026?
Sinovac Biotech Ltd (SVA) currently trades at $6.47 per share with a market capitalization of $642,437,000.00. Based on our multi-factor framework, the stock looks attractively valued with a Smart Value Score of 78/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 6.7x.
Our discounted cash flow model estimates SVA's intrinsic value at $22.06 per share, against the current market price of $6.47. This implies a margin of safety of +70.67%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: SVA looks attractively valued on our framework, with a Smart Value Score of 78/100. The combination of reasonable price, healthy growth, and quality fundamentals makes it worth serious consideration.
Frequently asked questions
Is SVA overvalued in 2026?
Based on a Smart Value Score of 78/100, SVA is not overvalued. Fundamentals support the current price and offer reasonable margin of safety.
What is SVA's fair value?
Our DCF model estimates SVA's intrinsic value at $22.06 per share, versus the current price of $6.47. This produces a margin of safety of +70.67%.
What P/E ratio does SVA trade at?
SVA trades at a P/E of 6.7x on trailing twelve-month earnings.
Is SVA a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 78/100 reflects the combined read on growth, quality, and price. The profile skews favorable for long-term accumulation.
How does SVA's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on SVA.
What is SVA's Smart Value Score?
SVA's Smart Value Score is 78/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.